Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM 1: Ceftazidime-Avibactam + Metronidazole vs Meropenem in cIAI
NCT01499290Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2012
- Primary completion
- Apr 2014
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of ceftazidime + avibactam in Intra-abdominal infection (IAI) (2 arms), sponsored by Pfizer. Primary endpoints: Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set, Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set and 1 more. Started Mar 2012; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT01499290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499290.